


PHARMACEUTICAL 2021



## PIERIS PHARMACEUTICALS INC. Rank 200 of 409







PHARMACEUTICAL 2021

PIERIS PHARMACEUTICALS INC. Rank 200 of 409



The relative strengths and weaknesses of PIERIS PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PIERIS PHARMACEUTICALS INC. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 82% points. The greatest weakness of PIERIS PHARMACEUTICALS INC. is the variable Research and Development, reducing the Economic Capital Ratio by 66% points.

The company's Economic Capital Ratio, given in the ranking table, is -127%, being 228% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	75,721
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	22,145
Liabilities, Non-Current	51,838
Other Assets	7,243
Other Compr. Net Income	1,700
Other Expenses	164
Other Liabilities	0
Other Net Income	-3,145
Property and Equipment	22,046
Research and Development	46,531
Revenues	29,323
Selling, General and Administrative Expense	16,713

Output Variable	Value in 1000 USD
Assets	105,010
Liabilities	73,983
Expenses	63,408
Stockholders Equity	31,027
Net Income	-37,230
Comprehensive Net Income	-36,380
Economic Capital Ratio	-127%

